黄热病

World Health Organization. Yellow fever: fact sheet. May 2023 [internet publication].全文

Staples JE, Bocchini JA Jr, Rubin L; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647-650.全文  摘要

Pan American Health Organization; World Health Organization. Laboratory diagnosis of yellow fever virus infection. September 2018 [internet publication].全文

1. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-856.全文  摘要

2. Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20. 摘要

3. World Health Organization. Yellow fever: fact sheet. May 2023 [internet publication].全文

4. World Health Organization. Disease outbreak news. Yellow fever - Mali. December 2019 [internet publication].全文

5. World Health Organization. Disease outbreak news. Yellow fever - Nigeria. December 2017 [internet publication].全文

6. World Health Organization. Disease outbreak news. Yellow fever - Nigeria. December 2019 [internet publication].全文

7. World Health Organization. Winning the war against yellow fever. November 2016 [internet publication].全文

8. World Health Organization. Weekly epidemiological record. Yellow fever in Africa and the Americas, 2017. August 2018 [internet publication].全文

9. Wilder-Smith A, Monath TP. Responding to the threat of urban yellow fever outbreaks. Lancet Infect Dis. 2017;17:248-250.全文  摘要

10. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-related infectious diseases - yellow fever. May 2023 [internet publication].全文

11. World Health Organization. Yellow fever in the WHO African and American Regions, 2010. Wkly Epidemiol Rec. 2011;86:370-6. 摘要

12. World Health Organization: Global Response and Alert (GAR). Yellow fever: a current threat. 2017 [internet publication].

13. Vasconcelos PF, Costa ZG, Travassos da Rosa ES, et al. Epidemic of jungle yellow fever in Brazil, 2000: implications of climatic alterations in disease spread. J Med Virol. 2001;65:598-604. 摘要

14. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411. 摘要

15. Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization - recommendations of the ACIP. MMWR Recomm Rep. 2011;60:1-64.全文  摘要

16. Centers of Disease Control and Prevention. Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:324-325.全文  摘要

17. Cornet JP, Huard M, Camicas JL, et al. Experimental transmission of the yellow fever virus by the tick Amblyomma variegatum (F.). Bull Soc Pathol Exot Filiales. 1982;75:136-140. 摘要

18. Staples JE, Bocchini JA Jr, Rubin L; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647-650.全文  摘要

19. World Health Organization.Yellow fever-Brazil. April 2019 [internet publication].全文

20. Pan American Health Organization, World Health Organization. Epidemiological update: yellow fever. Dec 2018 [internet publication].全文

21. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434-444. 摘要

22. Grobusch MP, Goorhuis A, Wieten RW, et al. Yellow fever revaccination guidelines change - a decision too feverish? Clin Microbiol Infect. 2013;19:885-886. 摘要

23. World Health Organization Department of Immunization, Vaccines and Biologicals. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. July 2016 [internet publication].全文

24. Casey RM, Harris JB, Ahuka-Mundeke S, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - final report. N Engl J Med. 2019 Aug 1;381(5):444-454.全文  摘要

25. Roukens AHE, van Halem K, de Visser AW, et al. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med. 2018 Dec 4;169(11):761-5. 摘要

26. Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review. Vaccine. 2011;29:4544-4555. 摘要

27. Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68:1267-1271. 摘要

28. Traiber C, Coelho-Amaral P, Ritter VR, et al. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J). 2011;87:269-272. 摘要

29. Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014;(1):CD010929.全文  摘要

30. Nascimento Silva JR, Camacho LA, Siqueira MM, et al; Collaborative Group for the Study of Yellow Fever Vaccines. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29:6327-6334. 摘要

31. Medicines and Healthcare products Regulatory Agency. Yellow fever vaccine: stronger precautions in people with weakened immunity and in those aged 60 years or older. November 2019 [internet publication].全文

32. Mirzaian E, Durham MJ, Hess K, et al. Mosquito-borne illnesses in travelers: a review of risk and prevention. Pharmacotherapy. 2010;30:1031-1043. 摘要

33. Pan American Health Organization; World Health Organization. Laboratory diagnosis of yellow fever virus infection. September 2018 [internet publication].全文

34. Drosten C, Göttig S, Schilling S, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323-2330.全文  摘要

35. Domingo C, Patel P, Yillah J, et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol. 2012;50:4054-4060. 摘要

36. Centers for Disease Control and Prevention. National Notifiable Disease Surveillance System (NNDSS): yellow fever, 2019 case definition. Apr 2021 [internet publication].全文

37. World Health Organization. CDC and WHO launch trial version of a new ELISA: a kit, simpler and faster to perform. July 2018 [internet publication].

38. World Health Organization.Yellow fever: case definitions for public health surveillance. May 2015 [internet publication].全文

39. Monath TP. Treatment of yellow fever. Antiviral Res. 2008;78:116-124. 摘要

40. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11(suppl 4):S750-S761. 摘要

41. Arroyo JI, Apperson SA, Cropp CB, et al. Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg. 1988;38:647-650. 摘要

42. Julander JG. Experimental therapies for yellow fever. Antiviral Res. 2013;97:169-179. 摘要

43. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination: United States, 2001-2002. MMWR Morb Mortal Wkly Rep. 2002;51:989-993.全文  摘要

44. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659-666. 摘要

45. ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis. 2004;190:1821-1827.全文  摘要

46. Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet. 2001;358:84-85. 摘要

47. Borio L, Inglesby T, Peters CJ, et al; Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287:2391-2405. 摘要

48. Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill. 2004;9:E11-E12.全文  摘要